# Oxiracetam
*Source: https://psychonautwiki.org/wiki/Oxiracetam*

## Dosage & Duration

### Oral

**Dosage:**
- Threshold: 250 mg
- Light: 500 - 1200 mg
- Common: 1200 - 1800 mg
- Strong: 1800 - 2400 mg
- Heavy: 2400 mg +

**Duration:**
- Total: 8 - 10 hours
- Onset: 30 - 90 minutes

**Oxiracetam** ( **ISF 2522** ) is a mild central nervous system [stimulant](https://psychonautwiki.org/wiki/Stimulant) and [nootropic](https://psychonautwiki.org/wiki/Nootropic) agent belonging to the [racetam](https://psychonautwiki.org/wiki/Racetam) family of drugs. Although it is one of the first known and synthesized derivatives of [piracetam](https://psychonautwiki.org/wiki/Piracetam) , its research and efficacy in humans is limited.

Oxiracetam is readily available and sold through online vendors as a dietary supplement in the United States. Dosages are nearly twenty times those of [noopept](https://psychonautwiki.org/wiki/Noopept) , making it less potent while offering comparable benefit.

Supplementation of oxiracetam tends to be in the dosage range of 1,200-2,400mg taken over the course of a day, either in two to three evenly spread dosing periods (such as three doses of 400mg or 800mg).

Oxiracetam has moderately protected against [scopolamine](https://psychonautwiki.org/wiki/Datura) -induced amnesia both in rat populations and in human populations, suggesting it can aid recovery from [deliriant](https://psychonautwiki.org/wiki/Deliriant) intoxication and other typically cognitively impaired states by preserving adequate levels of [acetylcholine](https://psychonautwiki.org/wiki/Acetylcholine) as a primary mechanism.

## Chemistry

Oxiracetam, or (RS)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide, is a synthetic compound of the [racetam](https://psychonautwiki.org/wiki/Racetam) family. Racetams share a [pyrrolidine](https://psychonautwiki.org/wiki/Pyrrolidine) nucleus, a five member nitrogenous ring with a ketone bonded oxygen at R 2 . This 2-pyrrolidone ring is bound to the terminal carbon of an acetamide group, an ethyl amide chain with a ketone bond (C=O) at the alpha carbon. Oxiracetam is substituted with an additional hydroxy group at R 4 , which is a chiral center for the molecule. Oxiracetam is presumably produced as a racemate of its enantiomers. Oxiracetam is structurally analogous to [piracetam](https://psychonautwiki.org/wiki/Piracetam) , which lacks the R 4 hydroxy substitution of oxiracetam.

## Pharmacology

Oxiracetam has been shown to increase [acetylcholine](https://psychonautwiki.org/wiki/Acetylcholine) release within hippocampal cells. As acetycholine is involved in the function of memory consolidation, this could potentially account for its [nootropic](https://psychonautwiki.org/wiki/Nootropic) effects.

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Stimulation](https://psychonautwiki.org/wiki/Stimulation)** - The stimulation which oxiracetam presents can be considered as primarily subtle, with a magnitude comparable to that of [caffeine](https://psychonautwiki.org/wiki/Caffeine) . ### Visual effects
 
- - **[Acuity enhancement](https://psychonautwiki.org/wiki/Acuity_enhancement)**
- **[Colour enhancement](https://psychonautwiki.org/wiki/Colour_enhancement)** ### Auditory effects
 
- - **[Enhancements](https://psychonautwiki.org/wiki/Auditory_enhancement)** ### Cognitive effects
 
- This effect listing primarily pertains to the recommended dosage. Users commonly report contradictory effects at higher (>2400mg) doses. 
- **[Wakefulness](https://psychonautwiki.org/wiki/Wakefulness)**
- **[Mindfulness](https://psychonautwiki.org/wiki/Mindfulness)**
- **[Analysis enhancement](https://psychonautwiki.org/wiki/Analysis_enhancement)**
- **[Thought connectivity](https://psychonautwiki.org/wiki/Thought_connectivity)**
- **[Focus enhancement](https://psychonautwiki.org/wiki/Focus_enhancement)**
- **[Motivation enhancement](https://psychonautwiki.org/wiki/Motivation_enhancement)**
- **[Memory enhancement](https://psychonautwiki.org/wiki/Memory_enhancement)**
- **[Dream potentiation](https://psychonautwiki.org/wiki/Dream_potentiation)**
### Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) . Additional experience reports can be found here:

- [Erowid Experience Vaults: Oxiracetam](https://erowid.org/experiences/subs/exp_Smarts_Oxiracetam.shtml)

## Toxicity and harm potential

Several studies suggest that this substance is safe even when high doses are consumed for a long period of time although it is worth noting that the exact toxic dosage is unknown. Anecdotal evidence from people who have tried oxiracetam within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this drug.

### Lethal dosage

The median lethal dosage ( [LD50](https://psychonautwiki.org/wiki/LD50) ) of oxiracetam has not been officially published as it has low abuse potential, but is not known to be harmful in it's recommended dosage range.

### Tolerance and addiction potential

The chronic use of oxiracetam can be considered as non-addictive with a low potential for abuse. It does not seem to be capable of causing psychological dependence among users, although this fact has not been corroborated by clinical studies. Tolerance to many of the effects of oxiracetam develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Oxiracetam may presents cross-tolerance with all [racetam](https://psychonautwiki.org/wiki/Racetam) [nootropics](https://psychonautwiki.org/wiki/Nootropic) , meaning that after the consumption of oxiracetam certain [nootropics](https://psychonautwiki.org/wiki/Nootropics) such as [aniracetam](https://psychonautwiki.org/wiki/Aniracetam) and [piracetam](https://psychonautwiki.org/wiki/Piracetam) may have a reduced effect.

## Legal status

Oxiracetam, being a member of the [racetam](https://psychonautwiki.org/wiki/Racetam) family, currently is legally available to buy and sell in most countries, but may still vary by region.

- **United Kingdom** - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use)
- [Pramiracetam](https://psychonautwiki.org/wiki/Pramiracetam)
- [Nootropic](https://psychonautwiki.org/wiki/Nootropic)
- [Stimulant](https://psychonautwiki.org/wiki/Stimulant)
- [Piracetam](https://psychonautwiki.org/wiki/Piracetam)

## External links

- [Oxiracetam (Wikipedia)](https://en.wikipedia.org/wiki/Oxiracetam)
- [Oxiracetam (Erowid Vault)](https://erowid.org/smarts/oxiracetam/oxiracetam.shtml)
- [Oxiracetam (TiHKAL / Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=9983)
- [Oxiracetam (Examine)](https://examine.com/supplements/Oxiracetam/)

## References
1. ↑ Malykh, A. G., Sadaie, M. R. (12 February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders".*Drugs*.**70**(3): 287–312.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2165/11319230-000000000-00000](//doi.org/10.2165%2F11319230-000000000-00000).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1179-1950](//www.worldcat.org/issn/1179-1950).
2. ↑ Valzelli, L., Baiguerra, G., Giraud, O. (June 1986). "Difference in learning and retention by Albino Swiss mice. Part III. Effect of some brain stimulants".*Methods and Findings in Experimental and Clinical Pharmacology*.**8**(6): 337–341.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0379-0355](//www.worldcat.org/issn/0379-0355).
3. ↑ Nootreviews Oxiracetam Guide | [http://nootreviews.com/oxiracetam](http://nootreviews.com/oxiracetam)
4. ↑ Preda, L., Alberoni, M., Bressi, S., Cattaneo, C., Parini, J., Canal, N., Franceschi, M. (1993). "Effects of acute doses of oxiracetam in the scopolamine model of human amnesia".*Psychopharmacology*.**110**(4): 421–426.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/BF02244648](//doi.org/10.1007%2FBF02244648).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0033-3158](//www.worldcat.org/issn/0033-3158).
5. ↑ Pitsikas, N., Algeri, S. (November 1992). "Effect of oxiracetam on scopolamine-induced amnesia in the rat in a spatial learning task".*Pharmacology, Biochemistry, and Behavior*.**43**(3): 949–951.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/0091-3057(92)90430-n](//doi.org/10.1016%2F0091-3057%2892%2990430-n).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0091-3057](//www.worldcat.org/issn/0091-3057).
6. ↑ Malykh, A. G., Sadaie, M. R. (12 February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders".*Drugs*.**70**(3): 287–312.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2165/11319230-000000000-00000](//doi.org/10.2165%2F11319230-000000000-00000).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1179-1950](//www.worldcat.org/issn/1179-1950).
7. ↑ Pugliese, A. M., Corradetti, R., Ballerini, L., Pepeu, G. (January 1990).["Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slices"](https://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.1990.tb14676.x).*British Journal of Pharmacology*.**99**(1): 189–193.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1111/j.1476-5381.1990.tb14676.x](//doi.org/10.1111%2Fj.1476-5381.1990.tb14676.x).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0007-1188](//www.worldcat.org/issn/0007-1188).
8. ↑ Parnetti, L., Mecocci, P., Petrini, A., Longo, A., Buccolieri, A., Senin, U. (1989). "Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia in comparison with a control group".*Neuropsychobiology*.**22**(2): 97–100.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1159/000118599](//doi.org/10.1159%2F000118599).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0302-282X](//www.worldcat.org/issn/0302-282X).
9. ↑ Itil, T. M., Menon, G. N., Songar, A., Itil, K. Z. (1986). "CNS pharmacology and clinical therapeutic effects of oxiracetam".*Clinical Neuropharmacology*. 9 Suppl 3: S70–72.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0362-5664](//www.worldcat.org/issn/0362-5664).
10. ↑ Perucca, E., Parini, J., Albrici, A., Visconti, M., Ferrero, E. (June 1987). "Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly".*European Journal of Drug Metabolism and Pharmacokinetics*.**12**(2): 145–148.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/BF03189889](//doi.org/10.1007%2FBF03189889).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0378-7966](//www.worldcat.org/issn/0378-7966).
11. ↑ [Psychoactive Substances Act 2016](https://www.legislation.gov.uk/ukpga/2016/2/contents/enacted)NewPP limit report Cached time: 20251218075702 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.029 seconds CPU time usage: 0.247 seconds Real time usage: 0.460 seconds Preprocessor visited node count: 1228/1000000 Post‐expand include size: 62431/2097152 bytes Template argument size: 3948/2097152 bytes Highest expansion depth: 11/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 14078/5000000 bytes Lua time usage: 0.150/7 seconds Lua virtual size: 7.44 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 363.687 1 -total 62.09% 225.802 9 Template:Cite_journal 17.95% 65.277 1 Template:SubstanceBox/Oxiracetam 16.68% 60.669 1 Template:SubstanceBox 7.65% 27.831 1 Template:Effects/base 6.70% 24.367 1 Template:Effect_list 5.69% 20.681 2 Template:Effect_column 4.10% 14.906 1 Template:Citation 1.84% 6.679 1 Template:Effects/physical 1.31% 4.763 1 Template:SummarySheet